| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015 |
| filingDate |
2006-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8de18ed147f5ade95dca25e272595361
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a9c9728d5c98aa9834a436d733a51b2 |
| publicationDate |
2006-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2006182788-A |
| titleOfInvention |
Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| abstract |
Disclosed is a pharmaceutical composition for the treatment of renal diseases such as acute and chronic renal failure or renal dysfunction. A composition comprising a type 4 (EP 4 ) receptor selective prostaglandin (PGE 2) agonist, in particular 5- (3-hydroxy-4-phenyl-but-1-enyl) which is a pyrrolidone derivative. ) -1- [6- (1H-tetrazol-5-yl) -hexyl] -pyrrolidin-2-one, 5- (3-hydroxy-4-phenyl-butyl) -1- [6- (1H-tetrazole- 5-yl) -hexyl] -pyrrolidin-2-one or 7- [2- (3-hydroxy-4-phenyl-but-1-enyl) -5-oxo-pyrrolidin-1-yl] -heptanoic acid Composition. [Selection figure] None |
| priorityDate |
2000-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |